DMCC Speciality Chemicals Limited (BOM:506405)
India · Delayed Price · Currency is INR 305.30
-7.70 (-2.46%)
At close: Aug 1, 2025
Longboard Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2021 |
Operating Revenue | 4,730 | 4,313 | 3,280 | 3,867 | 3,263 | 2,001 | Upgrade |
Other Revenue | 1.69 | - | - | - | - | - | Upgrade |
Revenue | 4,732 | 4,313 | 3,280 | 3,867 | 3,263 | 2,001 | Upgrade |
Revenue Growth (YoY) | 44.41% | 31.51% | -15.18% | 18.50% | 63.03% | 6.65% | Upgrade |
Cost of Revenue | 3,299 | 2,987 | 2,114 | 2,658 | 2,106 | 1,069 | Upgrade |
Gross Profit | 1,433 | 1,326 | 1,166 | 1,209 | 1,157 | 932.4 | Upgrade |
Selling, General & Admin | 289.23 | 277.13 | 242.63 | 243.05 | 207.15 | 168.22 | Upgrade |
Other Operating Expenses | 491.52 | 478.95 | 558.35 | 577.85 | 536.22 | 393.8 | Upgrade |
Operating Expenses | 948.21 | 923.28 | 956.06 | 994.88 | 823.97 | 630.32 | Upgrade |
Operating Income | 484.72 | 402.95 | 209.81 | 213.76 | 332.65 | 302.08 | Upgrade |
Interest Expense | -95.14 | -105 | -132.89 | -102.1 | -38.63 | -24 | Upgrade |
Interest & Investment Income | - | - | 4.11 | 1.54 | 2.83 | 3.44 | Upgrade |
Currency Exchange Gain (Loss) | - | - | -4.17 | -31.35 | -6.64 | -5.04 | Upgrade |
Other Non Operating Income (Expenses) | 13.44 | 13.44 | 10.93 | 12.18 | 48.31 | 63.93 | Upgrade |
EBT Excluding Unusual Items | 403.02 | 311.39 | 87.79 | 94.02 | 338.51 | 340.42 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | 84.43 | 9.87 | 0.1 | - | Upgrade |
Gain (Loss) on Sale of Assets | - | - | 0.28 | 2.09 | 2.84 | - | Upgrade |
Asset Writedown | - | - | - | -0.02 | -0.03 | - | Upgrade |
Pretax Income | 403.02 | 311.39 | 172.51 | 105.95 | 341.42 | 340.42 | Upgrade |
Income Tax Expense | 123.9 | 96.11 | 56.62 | 36.65 | 128.02 | 14.64 | Upgrade |
Net Income | 279.13 | 215.28 | 115.89 | 69.31 | 213.4 | 325.79 | Upgrade |
Net Income to Common | 279.13 | 215.28 | 115.89 | 69.31 | 213.4 | 325.79 | Upgrade |
Net Income Growth | 184.17% | 85.76% | 67.22% | -67.52% | -34.50% | 3.55% | Upgrade |
Shares Outstanding (Basic) | 25 | 25 | 25 | 25 | 25 | 25 | Upgrade |
Shares Outstanding (Diluted) | 25 | 25 | 25 | 25 | 25 | 25 | Upgrade |
Shares Change (YoY) | 0.03% | 0.02% | - | - | - | - | Upgrade |
EPS (Basic) | 11.19 | 8.63 | 4.65 | 2.78 | 8.56 | 13.06 | Upgrade |
EPS (Diluted) | 11.19 | 8.63 | 4.65 | 2.78 | 8.56 | 13.06 | Upgrade |
EPS Growth | 184.09% | 85.72% | 67.22% | -67.52% | -34.50% | 3.55% | Upgrade |
Free Cash Flow | - | 310.28 | 194.33 | 79.75 | -474.72 | -150.7 | Upgrade |
Free Cash Flow Per Share | - | 12.44 | 7.79 | 3.20 | -19.03 | -6.04 | Upgrade |
Dividend Per Share | - | 2.500 | 1.000 | - | 1.000 | 2.000 | Upgrade |
Dividend Growth | - | 150.00% | - | - | -50.00% | - | Upgrade |
Gross Margin | 30.28% | 30.75% | 35.55% | 31.26% | 35.45% | 46.59% | Upgrade |
Operating Margin | 10.24% | 9.34% | 6.40% | 5.53% | 10.20% | 15.09% | Upgrade |
Profit Margin | 5.90% | 4.99% | 3.53% | 1.79% | 6.54% | 16.28% | Upgrade |
Free Cash Flow Margin | - | 7.19% | 5.92% | 2.06% | -14.55% | -7.53% | Upgrade |
EBITDA | 655.25 | 570.16 | 363.71 | 386.45 | 412.05 | 370.38 | Upgrade |
EBITDA Margin | 13.85% | 13.22% | 11.09% | 9.99% | 12.63% | 18.50% | Upgrade |
D&A For EBITDA | 170.53 | 167.2 | 153.9 | 172.69 | 79.41 | 68.29 | Upgrade |
EBIT | 484.72 | 402.95 | 209.81 | 213.76 | 332.65 | 302.08 | Upgrade |
EBIT Margin | 10.24% | 9.34% | 6.40% | 5.53% | 10.20% | 15.09% | Upgrade |
Effective Tax Rate | 30.74% | 30.87% | 32.82% | 34.59% | 37.50% | 4.30% | Upgrade |
Revenue as Reported | 4,745 | 4,326 | 3,384 | 3,896 | 3,324 | 2,079 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.